Forest Announces Federal Court Upholds Lexapro(R) Patent
July 13 2006 - 9:05PM
PR Newswire (US)
NEW YORK, July 13 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX) said today that the U.S. District Court for the
District of Delaware has determined that the U.S. patent covering
escitalopram, the active ingredient in Lexapro(R), is both valid,
enforceable and infringed by Ivax/Teva's proposed generic product,
thereby confirming Forest's and Lundbeck's patent rights for
Lexapro(R), which expire in March 2012. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Judge
Joseph J. Farnan ruled in Forest's and Lundbeck's favor in a
lawsuit brought by Forest and its partner H. Lundbeck A/S of
Denmark against the generic manufacturer Ivax/Teva. The patent at
issue in the U.S. lawsuit is Lexapro's patent (U.S. Patent No. Re
34,712), which is set to expire in March 2012 and covers
substantially pure escitalopram. About Forest Laboratories Forest
Laboratories (http://www.frx.com/) is a US-based pharmaceutical
company dedicated to identifying, developing, and delivering
products that make a positive difference in peoples' lives. Forest
Laboratories' growing product line includes Lexapro(R)
(escitalopram oxalate), an SSRI indicated for adults for the
initial and maintenance treatment of major depressive disorder and
for generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer's disease; Benicar(R)*
(olmesartan medoxomil), an angiotensin receptor blocker, and
Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an
angiotensin receptor blocker and diuretic combination product, each
indicated for the treatment of hypertension; and Campral(R)*
(acamprosate calcium), indicated in combination with psychosocial
support for the maintenance of abstinence from alcohol in patients
with alcohol dependence who are abstinent at treatment initiation.
* Benicar is a registered trademark of Sankyo Pharma, Inc., and
Campral is a registered trademark of Merck Sante s.a.s., subsidiary
of Merck KGaA, Darmstadt, Germany. Except for the historical
information contained herein, this release contains
"forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, the
timely development and launch of new products, and the risk factors
listed from time to time in the Forest Laboratories' SEC reports,
including the Company's Annual Report on Form 10-K for the fiscal
year ended March 31, 2006.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano of Forest
Laboratories, Inc., Vice President, Investor Relations,
+1-212-224-6714, Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024